First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.

  Health   Dec 11, 2023   0   47  Add to Reading List
First-in-human clinical trial of CAR T cell therapy with new binding mechanism shows promising early responses

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

INCREASE YOUR SALES WITH NGN1,000 TODAY!

Advertise on doacWeb

WhatsApp: 09031633831

To reach more people from NGN1,000 now!

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial.
Read Original   

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow